General Info
California Institute for Regenerative Medicine provides funding for stem cell research at California universities and research institutions.
Location: San Francisco
Country:
Industries:
Investment Regions:
Investment Stages: late-stage, pre-seed, seed, series-a
Website: http://www.cirm.ca.gov/
corporate-vc
Want to start building warm intros with this investor?
🤖 AI Activity Report
Status: very-active
AI Reasoning: CIRM (California Institute for Regenerative Medicine) has multiple press releases in 2025 showing recent funding awards and grants to specific companies and projects, including an April 24, 2025 $8M award toward a vision loss gene therapy program and a March 27, 2025 $26.5M awards for clinical research and development; these are within the last 3 months window when measured from the required reference point, and examples of recipient organizations include Rocket Pharmaceuticals (trial update) and companies receiving vision gene therapy awards. Therefore the investor is classified as very-active.
Here are the thresholds established for the different statuses:
Not Active – No known investments in the last 12 months.
Low Activity – Only known investments between the last 12 and 6 months.
Active – Known investments between the last 6 and 3 months.
Very Active – Known investments in the last 3 months.
Investor Contact
Team Members
Name
Role
Email
LinkedIn
…
…
…
…
…
Warm Intros from Portfolio Companies
Investment Regions Map
loading map…
Similar Investors
Other similar investors:
Latest on X (Twitter)
Access all contact details of California Institute for Regenerative Medicine
Gain instant access to partner names, verified emails, LinkedIn profiles, and more—all in one place. Dive into their portfolio founders and their LinkedIn information, so you can quickly start your outreach and look for warm intros.
Add custom tags to your investor cards. Label them by investment stage, industry focus, interest level, or any other criteria you want to stay organized.
Trusted by Founders like You
Find your matching investors using AI